Helix will utilise the funding for expansion on consumer adoption of their products.
Temasek joined a $273.6m (US$200m) Series B funding for US-based genomics firm Helix. The company will use the said investment to continue improving consumer adoption of genomics through expansion, an announcement revealed.
“Temasek was the perfect partner for us to continue our growth into the rapidly expanding consumer genomics market both here in the United States and as we look to expand internationally in the coming years,” Helix CEO Robin Thurston said.
Also read: Temasek invests $341.65m in US tech firm
In early 2018, DFJ lead another investment round for Helix with other companies including Illumina, Warburg Pincus, Sutter Hill Ventures, Kleiner Perkins, Caufield Byers, and Mayo Clinic.
The San Francisco-headquartered firm provides DNA-powered products and services as well as some health and wellness products. It also operates an office in Denver Colorado and a sequencing laboratory in San Diego.
Do you know more about this story? Contact us anonymously through this link.